Endometrial preparation occurred during natural cycles for those with regular cycles, and artificial ones for those with irregular/anovulatory cycles. On the second day of menstruation, patients without uterine/ovarian issues were followed up for embryo transfer. When the follicle diameter was 16 to 20 mm, and luteinizing hormone level reached 15 IU/L and above, Ovitrelle (Ovitrelle, Merck Serono, Switzerland) triggered ovulation, and blastocyst transfer was performed 6 days after trigger. Crinone gel (Crinone 8%; Merck Serono, Switzerland) or Lutinus vaginal trophectoderm biopsy (TB) 2 × 100 mg (Lutinus 100 mg; Ferring, Germany) was used for luteal phase support. For the artificial cycle, the endometrium was prepared with a 2 mg Estradiol tablet (Estrofem, Novo Nordisk, Denmark) or a 3, 9 mg Estradiol patch (Climara, Bayer Turk, Turkey). Luteal phase support was initiated once the endometrium exceeded 7 mm after at least 12 days of estradiol valerate use as Crinone vaginal gel 2 × 1 or Lutinus 100 mg vaginal tablet 2 × 2. The β-hCG test was performed 9 days after blastocyst transfer. When this test was positive, a second β-hCG test was done 2 days later. The serum levels of hCG-β were determined using Chemiluminescence immunoassay (Abbott, Architect plus) with assay sensitivity of ≤ 1.2 m IU/mL.
Ovitrelle
Manufactured by Merck Group
Sourced in Germany, Switzerland, France, Italy, United Kingdom, Netherlands
Ovitrelle is a laboratory product manufactured by Merck Group. It is a gonadotropin-releasing hormone agonist used in in-vitro fertilization procedures.
Automatically generated - may contain errors
Lab products found in correlation
Gonal f, by Merck Group (71 mentions)
Cetrotide, by Merck Group (35 mentions)
Menopur, by Ferring (16 mentions)
Luveris, by Merck Group (10 mentions)
Cetrorelix, by Merck Group (9 mentions)
Gonapeptyl, by Ferring (7 mentions)
Decapeptyl, by Ferring (6 mentions)
Decapeptyl, by Ipsen (6 mentions)
Pregnyl, by Organon (5 mentions)
Puregon, by MSD (5 mentions)
Suprecur, by Sanofi (5 mentions)
Suprefact, by Sanofi (4 mentions)
Orgalutran, by MSD (4 mentions)
Menogon, by Ferring (3 mentions)
Menopur, by Merck Group (3 mentions)
Puregon pen, by Merck & Co (3 mentions)
Embryoscope, by Vitrolife (3 mentions)
Pregnyl, by MSD (3 mentions)
Synarela, by Pfizer (3 mentions)
Lucrin, by Abbott (3 mentions)
157 protocols using ovitrelle
1
Endometrial Preparation and Blastocyst Transfer Protocol
2
Dual Trigger to Minimize OHSS Risk
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum LH levels were analyzed in patients with a negative urine test only, using an automated electro-chemiluminescent immunoassay system (Roche Cobas e411 analyzer). The sensitivity for LH was 0.1 mIU/ml. Donors with no serum LH surge defined as LH <15 mIU/ml (12 (link)) at 12 h after injection and with more than 19 ovarian follicles >11 mm were given in the clinic by a nurse a dual trigger consisting of a bolus of GnRHa (0.2 ml Decapeptyl) and hCG, 1000 IU (Ovitrelle, Merck Serono) in order to minimize the risk of OHSS development; oocyte retrieval was subsequently performed 36 h after re-trigger. In donors with <19 follicles >11 mm, hCG 6500 UI (Ovitrelle, Merck Serono) was administered. Patients with a negative urine test, regardless of their serum LH levels, continued with GnRH antagonist the day of the serum LH testing until the new trigger was administered.
3
Ovarian Stimulation with GnRH Antagonist and FSH
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Ovarian stimulation was performed using a combination of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrotide; Merck Serono, Darmstadt, Germany) and FSH (Gonal-F; Serono, Geneva, Switzerland). Starting on the second day of the menstrual cycle, 150–225 IU/day of FSH was administered. When a follicle reached a size of 12–14 mm, GnRH antagonist injections were started, and continued until the follicle reached 17–18 mm. Recombinant human chorionic gonadotropin (Ovitrelle, Merck Serono, Germany) was then administered to trigger final maturation. Approximately 36 hours later, oocyte retrieval was performed using transvaginal ultrasonography-guided aspiration.
4
Ovarian Stimulation Protocols for IVF
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The ovarian stimulation protocol for IVF and the gonadotropin doses were chosen according to the woman's age and ovarian reserve markers. Long agonist or antagonist protocols were used. Ovarian stimulation was achieved with daily doses of 150–300 IU recombinant follicle stimulating hormone (FSHr) (Gonal‐F®; Merck‐Serono S.A., Madrid, Spain), alone or with the addition of 75 IU recombinant luteinizing hormone (LHr) (Luveris®; Merck‐Serono S.A.) or human menopausal gonadotropin (HMG) (Menopur®; Ferring SA, Madrid, Spain). Administration of human chorionic gonadotropin (hCG) (Ovitrelle®; 250 mg s.c., Merck‐Serono S.A.) was indicated in the presence of two or more follicles ≥ 18 mm in diameter, with four or more follicles measuring ≥ 14 mm in association with a consistent rise in serum estradiol concentration. Ultrasound‐guided transvaginal oocyte retrieval was performed 36 h after hCG administration.
5
Gonadotropin-Releasing Hormone Antagonist Protocol for IVF
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients were treated with GnRH antagonist protocol, as part of the COS of IVF treatment. Gonadotrophins (Gonal- F®; Serono, Hellas) were administered from day- 2 of the cycle, if the hormonal levels were basal. The initial dose of the gonadotrophins was predefined at 150- 300 IU for all patients and remained fixed for 5 days. After this period, the dose could be adjusted to each patient, according to the follicular growth and the estradiol levels.
Co- treatment with GnRH antagonist started on Day 6 of the stimulation with 0.25 mg cetrorelix (Merck-Serono) or 0.25 mg ganirelix (MSD).
The final oocyte maturation was induced when at least 3 follicles of 18 mm were present during ultrasound examination. Oocyte retrieval was performed 36 h after the administration of the triggering regimen. When <14 follicles were present, rec-HCG (Ovitrelle®; Merck-Serono) was administered. Alternatively, if ≥14 follicles were present, then agonist triggering was chosen with 0.3 mg Triptorelin (Arvekap®, IPSEN).
Co- treatment with GnRH antagonist started on Day 6 of the stimulation with 0.25 mg cetrorelix (Merck-Serono) or 0.25 mg ganirelix (MSD).
The final oocyte maturation was induced when at least 3 follicles of 18 mm were present during ultrasound examination. Oocyte retrieval was performed 36 h after the administration of the triggering regimen. When <14 follicles were present, rec-HCG (Ovitrelle®; Merck-Serono) was administered. Alternatively, if ≥14 follicles were present, then agonist triggering was chosen with 0.3 mg Triptorelin (Arvekap®, IPSEN).
6
Intrauterine Insemination Protocol for Ovarian Stimulation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients started ovarian stimulation 3 days after menstruation by taking daily subcutaneous gonadotropins (average dose of 83 UI/24 h, vide infra), as it has been described that this treatment increases pregnancy rates [22 (link)]. Transvaginal ultrasound was performed every 48 h to monitor ovarian response and endometrial thickness. The ovulation was triggered by the use of 250 μg of choriogonadotropin alpha (Ovitrelle®, Merck Serono, Darmstadt, Germany) when the dominant follicle reached 18 mm in diameter. Within 36 h of the ovulation trigger injection, semen samples were collected, and a swim-up was carried out following the method described before. Once conducted, 0.5 mL was loaded in a sterile syringe, and intrauterine insemination was conducted using a flexible cannula.
7
Ovulation Induction Protocols for IVF
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In order to stimulate ovulation, the long agonist protocol or the short antagonist protocol was used. The recombinant FSH (rFSH) or human menopausal gonadotropin (hMG) was administrated at a daily dose of 150-300 IU. In the case of the long protocol, pituitary desensibilization was achieved by the daily administration of a GnRH agonist (0.1 mg Gonapeptyl, Ferring Pharmaceuticals). The growth of follicles was monitored by transvaginal ultrasound examination and the measurement of serum estradiol levels (E2). In females qualified for the short antagonist protocol, the procedure of ovarian stimulation was started on the second day of the cycle. When the mean diameter of one of the follicles exceeded 14 mm or when the estradiol level was above 400 pg/ml, patients were administered 0.25 mg of Ganirelix (Orgalutran, Organon). After the diameter of the follicles was greater than 17 mm and the estradiol level was above 200 pg/ml per one follicle, the patient was administered subcutaneously 250 µg rhCG (Ovitrelle, Merck-Serono). Ovarian pick up (OPU) was performed under general intravenous anesthesia 36 hours following the injection of rhCG.
8
Gonadotrophin Therapy for Male Infertility
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Urine-derived gonadotrophin therapy, which had been in use until 2010, was changed to recombinant form. Intramuscular hCG treatment started with a dose of 1500 IU (twice per week) and adjusted according to testosterone levels and testicular development over 6 months. If the patient remained azoospermic at the end of 6 months, FSH treatment (75–150 IU, twice per week) was added to the regime. Target FSH levels of 4–6 IU were achieved by FSH dose adjustments. The follow-up protocol included the quarterly assessment of semen, and FSH and testosterone levels.
The recombinant forms of FSH and LH were Gonal F (Merck-Serono, Geneva, Switzerland) and Ovitrelle (Merck-Serono), respectively. The urine forms of FSH and LH were Menogon (Ferring, GmbH, Kiel, Germany) and Pregnyl (Organon, Oss, Netherlands), respectively.
The recombinant forms of FSH and LH were Gonal F (Merck-Serono, Geneva, Switzerland) and Ovitrelle (Merck-Serono), respectively. The urine forms of FSH and LH were Menogon (Ferring, GmbH, Kiel, Germany) and Pregnyl (Organon, Oss, Netherlands), respectively.
9
Crossover Comparison of rhCG Preparations
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The last part of the trial had an open randomized 2‐way crossover design comparing the PK and the testosterone release after administration of CG beta and CG alfa (Ovitrelle; Merck Serono) in 33 downregulated men. All men received 3 doses of 3.75 mg Decapeptyl in order to downregulate the pituitary‐gonadal axis and suppress testosterone to less than or equal to 1 ng/ml and LH to less than or equal to 2.5 IU/ml at the time of rhCG administration. Two doses of Decapeptyl were administered prior to the first drug administration on days −28 and −10 and a third dose was given on day 12 after the first dose of rhCG. A single dose of 125 µg rhCG of each preparation was administered s.c. in a crossover design with the 2 treatment periods ~ 3 weeks apart. Blood samples for measurement of serum hCG concentrations were obtained immediately before drug administration, and then at 4, 8, 12, 14, 16, 24, 36, 48, 72, 96, 120, 168, 216, and 264 h after each administration. Blood samples for measurement of serum testosterone concentrations were collected immediately before drug administration and then 4, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, and 264 h after each administration.
10
IVF Protocol for Male Infertility
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Normo-ovulatory young women (< 37 years of age) undergoing IVF due to male factor infertility or genetic indication for pre-implantation genetic diagnosis were selected for this study. Subjects carrier of Fragile X disorder, endometriosis and polycystic ovary syndrome (PCOS) were excluded. Ovarian stimulation was carried out as previously described [32 (link)]. Briefly, short antagonist protocol was used, consisted of ovarian suppression with GnRH antagonists (0.25 mg/day, Cetrorelix, Cetrotide; Merck Serono International) and controlled ovarian hyperstimulation with human menopausal gonadotropin (HMG; Menopur) or recombinant FSH, either Gonal-F; Merck Serono or Puregon, MSD. The initial dose used was dependent upon age, body mass index, and previous IVF treatment history. When three or more follicles exceeded18 mm in diameter, 250 μg of hCG (Ovitrelle; Merck Serono) was administered to trigger ovulation. Transvaginal follicular aspiration was performed 36 h later with ultrasound guidance.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!